enGene Holdings Inc. (NASDAQ:ENGNW) Short Interest Update

enGene Holdings Inc. (NASDAQ:ENGNW) was the target of a significant decrease in short interest in August. As of August 31st, there was short interest totaling 33,900 shares, a decrease of 28.5% from the August 15th total of 47,400 shares. Based on an average daily volume of 3,000 shares, the days-to-cover ratio is presently 11.3 days. Based on an average daily volume of 3,000 shares, the days-to-cover ratio is presently 11.3 days.

enGene Price Performance

NASDAQ ENGNW opened at $0.74 on Tuesday. The company has a 50 day simple moving average of $0.76 and a 200-day simple moving average of $0.74. enGene has a 52-week low of $0.51 and a 52-week high of $2.74.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.